Bedrijfsoverzicht
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical entity dedicated to the development of biologic therapeutics designed for individuals suffering from life-threatening medical conditions. The company operates within the Healthcare sector, specifically focusing on the Biotechnology industry, which entails high-risk, high-reward research and development cycles aimed at bringing novel treatments to market. The enterprise currently maintains a market capitalization of $1.10B while reporting annual revenue of $1.30M and employing a workforce of 109 individuals. These financial metrics indicate that the company possesses a significant market valuation relative to its current revenue stream, a characteristic often observed in early-stage biotechnology firms where investor capital is allocated based on potential pipeline value rather than established cash flows or profitability.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $1.30M, accompanied by a net income of $-140,055,008 and an EBITDA of $-132,542,000. The substantial gap between the modest revenue figure and the massive net loss reveals an aggressive cost structure driven primarily by the capital-intensive nature of clinical-stage drug development, where research and operational expenses far exceed current sales. Free cash flow stands at $-84,456,128, indicating that the company is currently burning through cash reserves to fund its operations and development programs rather than generating liquidity. All three margin metrics reflect this operational burn: the gross margin is 0.0%, the operating margin is -10386.5%, and the profit margin is 0.0%, collectively signaling that the company is not yet profitable and that costs are exceeding revenues by a wide margin. On the balance sheet, the company holds $124.22M in cash against $107.01M in debt, resulting in a debt-to-equity ratio of 1338.82, which suggests a highly leveraged financial position relative to its equity base. Despite the leverage, the current ratio of 3.93 indicates strong short-term liquidity, suggesting the company has sufficient current assets to cover its current liabilities several times over. Return on Equity is -197.8% and Return on Assets is -51.6%, metrics that reveal management is currently utilizing the company's capital base to generate significant losses rather than positive returns.
Waarderingsbeoordeling
Valuation metrics for the company present a complex picture given its lack of profitability, with a trailing P/E ratio of N/A and a forward P/E of -26.98. The negative forward P/E implies that the market is pricing in a trajectory where the company is expected to remain unprofitable or where earnings are negative in the near future. The price-to-book ratio stands at 137.35, indicating that the market values the company at a significant premium over its net asset value, a common valuation multiple for biotechnology firms with valuable intellectual property portfolios. Alternative valuation measures such as the price-to-sales ratio of 845.75 and the EV/EBITDA of -8.16 further illustrate that traditional profitability-based valuation models are not applicable, forcing reliance on revenue multiples or pipeline potential. The stock price has fluctuated significantly over the past year, ranging from a 52-week low of $10.84 to a 52-week high of $94.56. Without a specific current price provided in the source data to calculate the exact percentage deviation, the metrics confirm a high degree of price volatility inherent in the biotechnology sector. The beta value is listed as N/A, meaning there is no available historical data to quantify the stock's volatility relative to the broader market index.
Growth & Income
Growth dynamics for Inhibrx Biosciences, Inc. show a revenue growth rate of -100.0% year-over-year, while earnings growth is listed as N/A. The negative revenue growth indicates a contraction in sales or a cessation of reporting sales for the trailing period, and since earnings are N/A or negative, the concept of earnings growing faster or slower than revenue is currently not applicable in a traditional sense. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that it does not distribute profits to shareholders. The 0.0% payout ratio is theoretically sustainable given that the company has no earnings to distribute, but the capital is instead retained to fund ongoing research and development efforts. Consequently, the company reinvests its limited financial resources directly into advancing its therapeutic candidates rather than paying out income to investors. The overall growth and income profile is characterized by a complete lack of current profitability, negative revenue growth, and a capital allocation strategy focused entirely on future clinical milestones rather than current shareholder returns.